Literature DB >> 3260819

Induction of lymphokine-activated killer cells from rat thymocytes using recombinant human interleukin-2.

H Imaya1, H Matsuura, M Kudo, S Nakazawa.   

Abstract

Using a 4-h 51Cr release assay, we observed that thymocytes from Fischer strain rats incubated with recombinant human interleukin-2 (rhIL-2) developed cytotoxicity to YAC-1 lymphoma, 9L-glioma, and B-16 melanoma cells (effector/target ratio = 25/1). Induction of the lymphokine-activated killer (LAK) cells was as follows: (1) when 5 x 10(6)/ml thymocytes were cultured with various concentrations of rhIL-2 (50, 125, 250, 500, or 1,000 units/ml) for 4 days, no cell proliferation was observed at any concentration. However, the LAK cells showed significant cytotoxicity toward all tumor cells at more than 50 units/ml. (2) When 5 x 10(6)/ml thymocytes were cultured for 1 to 6 days with 250 units/ml of rhIL-2, the harvested cell count decreased markedly after the 2nd day. The cytotoxicity of all the tumor cells became significant after the 2nd day, with peak activity on the 4th day. In rat splenocytes, on the other hand, the LAK cells could not be identified because rat splenocytes developed nonspecific cytotoxicity in medium containing fetal calf serum without adding rhIL-2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260819     DOI: 10.1007/bf00205752

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  12 in total

1.  Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells.

Authors:  S K Jacobs; G Melin; B Holcomb; C W Parham; P L Kornblith; E A Grimm
Journal:  Brain Res       Date:  1986-05-07       Impact factor: 3.252

2.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

3.  Direct demonstration that the monoclonal antibody AMT-13 and interleukin 2 bind to the same molecule.

Authors:  H Osawa; T Diamantstein
Journal:  Eur J Immunol       Date:  1985-03       Impact factor: 5.532

4.  Fetal calf serum-induced blastogenic and cytotoxic responses of human lymphocytes.

Authors:  J V Zielske; S H Golub
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

5.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

Authors:  M Rosenstein; I Yron; Y Kaufmann; S A Rosenberg
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

6.  Immunoregulation and immunostimulation of murine lymphocytes by recombinant human interleukin-2.

Authors:  J E Talmadge
Journal:  J Biol Response Mod       Date:  1985-02

7.  Induction of interleukin 2 responsiveness in thymocytes by synergistic action of interleukin 1 and interleukin 2.

Authors:  D N Männel; S B Mizel; T Diamantstein; W Falk
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

8.  In vitro augmentation of rat natural killer (NK) cell activity.

Authors:  C W Reynolds; R B Herberman
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

9.  Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.

Authors:  N K Damle; L V Doyle; E C Bradley
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

10.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  1 in total

1.  Comparison of lymphokine-activated killer activities between thymocytes and splenocytes in rats with brain tumors.

Authors:  H Matsuura; H Imaya
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.